Abstract
Alemtuzumab (ALEM) is an anti-CD52 monoclonal antibody approved for the treatment of active Multiple Sclerosis(MS) which showed high efficacy also in the subgroup of highly-active patients. We aimed to evaluate efficacy/safety profile of ALEM-treatment in a population of aggressive MS naïve-patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
